Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H7N9 VLP Vaccine with Matrix-M1 in Healthy Adults
NCT02078674Phase 2Completed
- Sponsor
- Novavax
- Start
- Mar 2014
- Primary completion
- Jul 2015
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of H7N9 Pandemic Influenza VLP Vaccine in Avian influenza A (H7N9), sponsored by Novavax. Started Mar 2014; status: completed.
02
Drugs
H7N9 Pandemic Influenza VLP Vaccine
03
Conditions
Avian influenza A (H7N9)
Beyond the preview
Go deeper on NCT02078674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078674.